Rx-360 Welcomes New CEO/COO
James M. Fries
(301) 710-9399, Ext. 101
Today, Rx-360 announced the appointment of James ‘Jim’ M. Fries to the position of Chief Executive Officer/Chief Operating Officer (CEO/COO) of the international pharmaceutical supply chain consortium. This appointment follows the successful growth of the organization since its foundation in 2009 in the aftermath of the adulterated heparin tragedy. Jim will provide leadership to a vibrant organization of 300 volunteers from over 100 institutions that are organized in 17 working groups with activities in the United States, Europe, China and India.
Rx-360’s CEO/COO will lead the consortium and its membership in executing the Board’s Strategic Plan, expanding its membership and creating global awareness of Rx-360’s central mission: To protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain.
“I am delighted to welcome Jim Fries to the consortium. We are confident that Jim will lead the organization in a way that promotes growth and brings value to the members. With Jim’s strategic vision and ‘roll up the sleeves mentality’, he is sure to lead the consortium to success.” says Gwyn Murdoch, Rx-360 Chair.
Jim Fries is a success based executive with over 20 years of experience building medical device and diagnostic companies from a sales, market access, and external validation standpoint.
Jim’s strategic vision, as well as his roll up the sleeves mentality, is creative and has been proven as a best practice in achieving both short and long-term goals. That vision and creative thinking has resulted in Jim being a key member of executive leadership teams that have driven towards and successfully completed high yield acquisitions and public offerings. His leadership style has consistently been described as collaborative, mentoring, and accountable. He believes every employee hired and every decision made by a company is an investment. His true calling is to make sure there is a return on that investment.
As an individual contributor, Jim, has successfully built and managed sales/business development teams that have exceeded growth expectations. He has successfully developed and integrated not only customer retention and acquisition programs but also built sales, clinical, regulatory, and market access teams for multiple organizations. Jim has also managed key opinion leader and advisory boards for multiple companies which resulted in published consensus papers and peer sales/marketing initiatives. His formal collaborations both commercially and development wise within multiple disease states have been benchmarks in driving value within growth oriented companies.
Jim’s Career Highlights/Timeline:
- VNUS Medical Technologies 2002 (acquired by Covidien) Director, Market Access
- LipoScience 2011 (acquired by Labcorp) Vice President, External Affairs (Marketing)
- Novasys Medical 2013 (acquired by Verathon) Vice President, External Relations
- Vascular insights 2014 Chief Commercial Officer
- OrthoForge 2017 Chief Executive Officer
Jim’s start date is Feb. 8, 2018 and he will be located at the Rx-360 office in New Market, MD. Please feel free to contact Jim directly should you have any questions: [email protected]
Rx-360, an international pharmaceutical supply chain consortium, was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain. The organization’s mission is to protect patient safety by sharing information and developing processes related to the integrity of the healthcare supply chain and the quality of materials within the supply chain. To fulfill this mission, Rx-360 has work streams related to: conduction and sharing of audits, supply chain security, monitoring and reporting, Asia-focused efforts, supplier-focused efforts, and external relations, communications, and membership. To learn more about Rx-360, please visit http://www.Rx-360.org or email [email protected].